Afraxis Grants Exclusive Global License to Genentech

SAN DIEGO, Jan. 29, 2013 /PRNewswire/ -- Afraxis, Inc. today announced that it has entered into a global licensing agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to develop compounds for an undisclosed novel target. Under the terms of the agreement, Genentech will have exclusive, worldwide rights to develop and commercialize Afraxis' proprietary compounds. Afraxis is eligible to receive upfront, research, development and commercialization milestone payments, together totaling up to $187.5 million. Full financial terms have not been disclosed.

"Afraxis has secured this relationship with Genentech only five years after founding the company as part of Avalon's life sciences portfolio," said Jay Lichter, Ph.D., president and CEO of Afraxis, and managing partner of Avalon Ventures. "Avalon's approach to investing in companies at the earliest stages and staying actively involved in company management is proving to be a successful strategy for life science investing."

About Afraxis, Inc.

Afraxis, Inc. is a San Diego-based biotechnology company fully funded by Avalon Ventures.

For more information visit the Afraxis Web site: www.afraxis.com

SOURCE Afraxis, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
//-->